CytomX Therapeutics News and Activities
Presence
CytomX Therapeutics develops antibody-based medicines for cancer. Its products and services include oncology drug candidates, research collaborations, and platform technology for pharmaceutical partners and patients with hard-to-treat tumors.
CytomX Therapeutics products and services overview:
- Cancer therapeutics
- Antibody medicines
- Drug discovery
- Research partnerships
- Platform technology
Revenue: ~$56 million
Employees: 140
Headquarters: South San Francisco, United States (USA)
CytomX Therapeutics is one of the...
CytomX Therapeutics is a company listed under the stock ticker CTMX (US).
Acquisition, funding and merger involving CytomX Therapeutics.
- CytomX Therapeutics has just announced a $250 Million fundraising (posted on April 23 2026).
- CytomX Therapeutics has just announced a $250 Million fundraising (posted on April 23 2026).
Executives
View the org chart displaying its 23 main executives
Most searched biographies at CytomX Therapeutics
- Sean McCarthy, President, Chief Executive Officer and Chairman of ...
- Matthew Young, Director
- James Meyers, Director
Popular executive movements at CytomX Therapeutics
- Mamata Gokhale has joined the company as Senior Vice President of Regulatory Affairs (posted on May 18 2026).
Create your alert
to follow the executive moves at CytomX Therapeutics.
Biotechnology
CytomX Therapeutics has 2,435 competitors including Vertex Pharmaceuticals (United States (USA)), Lonza (Switzerland) and Eurofins (Luxembourg).
Popular M&A news in Biotechnology
- Crystalys Therapeutic has just announced a $130 Million fundraising (posted on July 23 2026).
- Ipsen has acquired Memo Therapeutics (posted on July 22 2026).
- AdvanCell has just announced a $315 Million fundraising (posted on July 21 2026).
Popular contacts in Biotechnology
News
Press releases by CytomX Therapeutics
- CytomX Therapeutics to Present at Upcoming Virtual August Investor Conferences | CytomX Therapeutics, Inc.
- CytomX Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022 | CytomX Therapeutics, Inc.
- CytomX Therapeutics Provides Strategic Update | CytomX Therapeutics, Inc.
- CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer | CytomX Therapeutics, Inc.
- CytomX Therapeutics Announces New Employment Inducement Grants | CytomX Therapeutics, Inc.
- CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference | CytomX Therapeutics, Inc.
- CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors | CytomX Therapeutics, Inc.
- CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update | CytomX Therapeutics, Inc.
- CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022 | CytomX Therapeutics, Inc.
- Press Releases | CytomX Therapeutics, Inc.
- View more press releases Close
Social media about CytomX Therapeutics
- CytomX Therapeutics on Wikipedia, Google News & Yahoo Finance
- CytomX Therapeutics on LinkedIn, X (Twitter) & YouTube
